New Drug Development Costs and Clinical Research
This paper analyzes the escalating costs of clinical drug development and their impact on the pharmaceutical industry's ability to innovate. Drawing on three major sources—a Forbes analysis, the Adams and Brantner (2006) cost study, and The Economist's report on patent disputes—the paper demonstrates that development costs exceed $800 million per drug, with leading companies spending up to $5.5 billion. The analysis reveals how high failure rates, economies of scale, and international patent conflicts shape drug availability and pricing. The paper concludes that regulatory reform is needed to balance pharmaceutical innovation with consumer access to affordable medications.
- Introduction: High drug development costs slow pharmaceutical innovation
- Forbes Report on Drug Development Costs: Analysis of drug failure rates and billion-dollar development costs
- Cost Analysis: Adams and Brantner Study: Peer-reviewed quantification of preclinical and clinical expenses
- Patent Disputes and International Access: Global policy conflicts over drug pricing and patent protection
- Summary and Conclusion: Policy recommendations for affordable drug access
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Synthesizes three authoritative sources (Forbes, peer-reviewed health research, and The Economist) to build a multifaceted argument about drug costs.
- Uses concrete financial data and specific examples (the $350 million to $5.5 billion range, the 95% failure rate, Maine's online pharmacy policy) to ground abstract claims about industry barriers.
- Structures the argument logically: establishes the scale of the problem, shows the data backing it, then illustrates real-world consequences via policy disputes and access issues.
Key academic technique demonstrated
The paper demonstrates comparative source analysis. Rather than relying on a single study, the author presents three independent investigations into overlapping aspects of the drug cost problem—each offering a different lens (industry reporting, formal health economics research, and international policy journalism). This allows the reader to see the issue from multiple angles and increases credibility through corroboration.
Structure breakdown
The paper follows a problem-evidence-implications structure. The introduction frames high development costs as the central issue. Three body sections each introduce a source and extract its key findings: Forbes establishes the magnitude of costs and failure rates; Adams and Brantner provide peer-reviewed quantification and discussion of company-size effects; The Economist shifts focus to consequences—showing how high costs and patent protections affect access globally. The conclusion synthesizes these findings into a policy argument for reform.
Introduction
The objective of this study is to examine the future of clinical research with a focus on new drug costs. Toward this end, three reports will be examined that analyze this issue. Drug development costs are extraordinarily high, and this results in pharmaceutical companies being slow to develop drugs. Understanding these barriers is essential to addressing healthcare innovation and patient access to new treatments.
Create your account
Always verify citation format against your institution’s current style guide requirements.